This document summarises the Life Saving Drugs Program Expert Panel's consideration of the application from Alexion Pharmaceuticals Australasia Pty Ltd to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of perinatal- and infantile-onset hypophosphatasia (HPP).
The document contains:
- Overview
- Background
- PBAC Consideration
- Consumer Input
- LSDP Expert Panel Consideration
- Funding Criteria
- Pricing Issues
- Treatment Guidelines
- Management of Uncertainties
- Context
- Sponsor’s Comment
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English